| 12.2 12.2 (-9.96%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.22 | 1-year : | 18.94 |
| Resists | First : | 13.89 | Second : | 16.22 |
| Pivot price | 11.07  |
|||
| Supports | First : | 11.39 | Second : | 9.85 |
| MAs | MA(5) : | 12.37 |
MA(20) : | 10.98 |
| MA(100) : | 9.49 |
MA(250) : | 9.1 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 80.1 |
D(3) : | 85.8 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 14.93 | Low : | 4.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELTX ] has closed below upper band by 22.5%. Bollinger Bands are 85.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.61 - 13.68 | 13.68 - 13.72 |
| Low: | 12.05 - 12.13 | 12.13 - 12.19 |
| Close: | 12.08 - 12.21 | 12.21 - 12.29 |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Thu, 16 Apr 2026
New Elicio hire gets 21,210 stock options at $11.78 a share - Stock Titan
Thu, 16 Apr 2026
Press Release: Elicio Therapeutics Reports Inducement Grants - Elicio Therapeutics
Thu, 16 Apr 2026
ELTX SEC Filings - Elicio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 15 Apr 2026
Ladenburg Thalmann initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
Sun, 22 Mar 2026
If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan
Thu, 12 Mar 2026
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Elicio Therapeutics
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 30.8 (%) |
| Held by Institutions | 13.9 (%) |
| Shares Short | 1,310 (K) |
| Shares Short P.Month | 1,300 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -4.73 |
| PEG Ratio | 0 |
| Price to Book value | 135.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|